CH413235A - Verfahren zur Kultivierung von menschlichen Erkältungsviren - Google Patents

Verfahren zur Kultivierung von menschlichen Erkältungsviren

Info

Publication number: CH413235A
Authority: CH; Switzerland
Prior art keywords: medium; cells; cultivation; incubation; virus
Prior art date: 1960-01-28

Application number

CH85761A

Other languages

German (de)

English (en)

Inventor

John Tyrrell David Arthur

Original Assignee

Nat Res Dev

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1960-01-28

Filing date

1961-01-25

Publication date

1966-05-15

1960-01-28 Priority claimed from GB3162/60A external-priority patent/GB930720A/en

1961-01-25 Application filed by Nat Res Dev filed Critical Nat Res Dev

1966-05-15 Publication of CH413235A publication Critical patent/CH413235A/de

Links

241000700605 Viruses Species 0.000 title claims description 40
238000000034 method Methods 0.000 title claims description 20
210000004027 cell Anatomy 0.000 claims description 22
238000011534 incubation Methods 0.000 claims description 16
238000002360 preparation method Methods 0.000 claims description 10
230000000694 effects Effects 0.000 claims description 8
239000000463 material Substances 0.000 claims description 8
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 6
210000003292 kidney cell Anatomy 0.000 claims description 6
238000010998 test method Methods 0.000 claims description 6
238000012360 testing method Methods 0.000 claims description 6
238000004519 manufacturing process Methods 0.000 claims description 4
239000012064 sodium phosphate buffer Substances 0.000 claims description 4
-1 alkali metal bicarbonate Chemical class 0.000 claims description 3
235000017557 sodium bicarbonate Nutrition 0.000 claims description 3
229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 3
229910052783 alkali metal Inorganic materials 0.000 claims description 2
230000003115 biocidal effect Effects 0.000 claims description 2
239000002356 single layer Substances 0.000 claims description 2
239000003429 antifungal agent Substances 0.000 claims 1
229940121375 antifungal agent Drugs 0.000 claims 1
239000002609 medium Substances 0.000 description 21
229960005486 vaccine Drugs 0.000 description 10
210000001519 tissue Anatomy 0.000 description 8
241000282693 Cercopithecidae Species 0.000 description 6
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 6
102000004407 Lactalbumin Human genes 0.000 description 4
108090000942 Lactalbumin Proteins 0.000 description 4
244000309466 calf Species 0.000 description 4
239000010410 layer Substances 0.000 description 4
210000002966 serum Anatomy 0.000 description 4
241000282412 Homo Species 0.000 description 3
229930182555 Penicillin Natural products 0.000 description 3
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 3
238000012258 culturing Methods 0.000 description 3
239000001963 growth medium Substances 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
229940049954 penicillin Drugs 0.000 description 3
150000003839 salts Chemical class 0.000 description 3
239000000243 solution Substances 0.000 description 3
229960005322 streptomycin Drugs 0.000 description 3
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
210000004102 animal cell Anatomy 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
230000000120 cytopathologic effect Effects 0.000 description 2
230000007850 degeneration Effects 0.000 description 2
210000002257 embryonic structure Anatomy 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
230000036039 immunity Effects 0.000 description 2
208000015181 infectious disease Diseases 0.000 description 2
230000002458 infectious effect Effects 0.000 description 2
238000011081 inoculation Methods 0.000 description 2
239000000543 intermediate Substances 0.000 description 2
210000003734 kidney Anatomy 0.000 description 2
230000003902 lesion Effects 0.000 description 2
239000007788 liquid Substances 0.000 description 2
229940049018 mycostatin Drugs 0.000 description 2
VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 2
239000002245 particle Substances 0.000 description 2
210000005084 renal tissue Anatomy 0.000 description 2
239000000725 suspension Substances 0.000 description 2
238000005406 washing Methods 0.000 description 2
102000009027 Albumins Human genes 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
241000709661 Enterovirus Species 0.000 description 1
241000282567 Macaca fascicularis Species 0.000 description 1
241000282560 Macaca mulatta Species 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
239000000427 antigen Substances 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
239000000872 buffer Substances 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
239000012141 concentrate Substances 0.000 description 1
238000000502 dialysis Methods 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
239000000417 fungicide Substances 0.000 description 1
230000000521 hyperimmunizing effect Effects 0.000 description 1
238000005342 ion exchange Methods 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
244000005700 microbiome Species 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
201000009240 nasopharyngitis Diseases 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
230000007505 plaque formation Effects 0.000 description 1
239000012266 salt solution Substances 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000011343 solid material Substances 0.000 description 1
239000000126 substance Substances 0.000 description 1
238000005199 ultracentrifugation Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/125—Picornaviridae, e.g. calicivirus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32711—Rhinovirus
- C12N2770/32734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32711—Rhinovirus
- C12N2770/32751—Methods of production or purification of viral material
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32711—Rhinovirus
- C12N2770/32761—Methods of inactivation or attenuation
- C12N2770/32764—Methods of inactivation or attenuation by serial passage

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Virology (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Medicinal Chemistry (AREA)
Microbiology (AREA)
Public Health (AREA)
Zoology (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Mycology (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Genetics & Genomics (AREA)
Wood Science & Technology (AREA)
Biotechnology (AREA)
Biochemistry (AREA)
General Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

CH85761A 1960-01-28 1961-01-25 Verfahren zur Kultivierung von menschlichen Erkältungsviren CH413235A (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GB3162/60A GB930720A (en)	1960-01-28	1960-01-28	Cultivation of human cold virus
GB3801460		1960-11-04

Publications (1)

Publication Number	Publication Date
CH413235A true CH413235A (de)	1966-05-15

Family

ID=26238103

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CH85761A CH413235A (de)	1960-01-28	1961-01-25	Verfahren zur Kultivierung von menschlichen Erkältungsviren

Country Status (5)

Country	Link
BE (1)	BE599028A (da)
CH (1)	CH413235A (da)
DK (1)	DK102759C (da)
ES (1)	ES264136A1 (da)
FR (1)	FR1302385A (da)

1961
- 1961-01-12 BE BE599028A patent/BE599028A/fr unknown
- 1961-01-19 ES ES0264136A patent/ES264136A1/es not_active Expired
- 1961-01-25 CH CH85761A patent/CH413235A/de unknown
- 1961-01-27 FR FR850929A patent/FR1302385A/fr not_active Expired
- 1961-01-28 DK DK38161A patent/DK102759C/da active

Also Published As

Publication number	Publication date
DK102759C (da)	1965-10-04
FR1302385A (fr)	1962-08-31
BE599028A (fr)	1961-05-02
ES264136A1 (es)	1961-05-16

Publication	Publication Date	Title
DE1617940C2 (de)	1985-05-30	Verfahren zur Gewinnung eines für die Züchtung von Viren geeigneten Zellstammes
DE2713371C2 (da)	1989-01-05
CH617588A5 (da)	1980-06-13
DE2463143C2 (de)	1985-04-11	Polyvalente Rindervirus-Lebendimpfstoffe
DE2362067C2 (de)	1985-11-28	Temperaturempfindliche, nicht-pathogene, infektiöse Rinder-Rhinotracheitis-Virusstämme, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung von Lebendimpfstoffen
DE2828073C2 (de)	1983-05-05	Verfahren zum Kultivieren von Viren
DD232822A5 (de)	1986-02-12	Verfahren zur herstellung eines viruspraeparates gegen die mareksche gefluegelkrankheit
DE1198489B (de)	1965-08-12	Verfahren zur Herstellung eines Impfstoffes gegen Panleucopenie
AT231068B (de)	1964-01-10	Verfahren zur Herstellung von Vaccinzwischenprodukten
CH413235A (de)	1966-05-15	Verfahren zur Kultivierung von menschlichen Erkältungsviren
DE2854723C3 (de)	1982-03-25	Hetero-Impfstoff zur therapeutischen Behandlung des Trichomonas -Syndroms und Verfahren zu seiner Herstellung
DE2805311A1 (de)	1978-09-21	Respiratorische synzytial-vakzine
CH667204A5 (de)	1988-09-30	Pharmazeutisches praeparat enthaltend lebende vermehrungsfaehige embryonalzellen, verfahren zu dessen herstellung und verfahren zum testen der pharmazeutischen wirksamkeit.
DE1163497B (de)	1964-02-20	Verfahren zum Zuechten von Erkaeltungsviren
DE2162013C3 (de)	1981-10-15	Tollwut-Lebendimpfstoff, Verfahren zu seiner Herstellung nd seine Verwendung bei der Bekämpfung von Tollwut
AT246922B (de)	1966-05-10	Verfahren zur Herstellung einer Vakzine aus lebenden, abgeschwächten Masernviren
DE2225548A1 (de)	1973-12-06	Intravenoes vertraegliche staupe- und hepatitisvaccine
DE2111120C3 (de)	1974-10-17	Verfahren zur Herstellung von Rubella-Virus-Hämagglutinationsantigen
DE2129777C3 (de)	1982-04-15	Verfahren zur Herstellung eines stark ageschwächte Rötelviren enthaltenden Impfstoffes
DE1007473B (de)	1957-05-02	Verfahren zur Herstellung eines Poliomyelitis-Impfstoffes
DE2132911C2 (de)	1984-01-19	Verfahren zum Herstellen eines stark abgeschwächte Rötelviren enthaltenden Impfstoffs
AT92081B (de)	1923-04-10	Verfahren zur Herstellung von avirulenten Heil- und Schutzstoffen für Tuberkulose.
AT234902B (de)	1964-07-27	Verfahren zur Herstellung einer Vaccine gegen Staupe
DE2517550C3 (de)	1982-05-06	Verfahren zum Herstellen eines Lebend-Impfstoffs zum Immunisieren von fleischfressenden Tieren gegen Staupe
DE1021128B (de)	1957-12-19	Verfahren zur Herstellung eines Impfstoffes gegen die Rhinotracheitis der Rinder